Treatment of giant cell arteritis - current approach and new possibilities

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Giant Cell Arteritis (GCA) is a systemic autoimmune vasculitis targeting large arteries like the aorta.
• It predominantly affects individuals aged 50 and older, representing the most common systemic vasculitis.
• Key symptoms include headaches, jaw claudication, and polymyalgia rheumatica, with a significant risk of acute vision loss from optic ischemia.

Purpose of the Study:

• To provide a comprehensive overview of Giant Cell Arteritis (GCA).
• To detail diagnostic methods, including clinical findings, imaging, and biopsy.
• To outline current and emerging therapeutic strategies for GCA management.

Main Methods:

• Diagnosis relies on a combination of clinical presentation, laboratory tests, and imaging modalities such as PET/CT.
• Histological confirmation via temporal artery biopsy remains a critical diagnostic component.
• Treatment involves immunosuppressive therapy, primarily systemic glucocorticoids, with adjuncts like methotrexate and tocilizumab.

Main Results:

• GCA diagnosis integrates clinical suspicion with objective findings from imaging and biopsy.
• Effective management requires prompt initiation of immunosuppressive therapy to mitigate complications.
• Ongoing clinical trials are exploring novel biological agents for enhanced GCA treatment.

Conclusions:

• Giant Cell Arteritis is a serious condition requiring prompt diagnosis and management.
• Current treatments focus on glucocorticoids, with established roles for methotrexate and tocilizumab.
• Future therapies involving biological agents hold promise for improving GCA outcomes.